- Previous Close
23.19 - Open
23.12 - Bid 22.86 x --
- Ask 22.87 x --
- Day's Range
22.73 - 23.48 - 52 Week Range
18.17 - 28.58 - Volume
13,057,799 - Avg. Volume
9,162,722 - Market Cap (intraday)
14.379B - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
19.21 - EPS (TTM)
1.19 - Earnings Date --
- Forward Dividend & Yield 1.20 (5.25%)
- Ex-Dividend Date Oct 10, 2024
- 1y Target Est
--
Jiang Zhong Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of Chinese patent medicines and health foods in Mainland China. The company offers OTC products for spleen and stomach, intestinal tract, anorectal, throat cough and asthma, supplements and minerals, and chronic diseases. It also offers health products for high-end nourishment, rehabilitation nutrition, gastrointestinal health, liver and gallbladder health, dietary nutrition, basic vitamins, personal care essential oils, and other businesses; and prescription products. The company sells its products under the Jiangzhong, Lihuo, Chuyuan, Shenlingcao, Yang Jisheng, and Songhai brands. Jiang Zhong Pharmaceutical Co.,Ltd was founded in 1969 and is headquartered in Nanchang, China. Jiang Zhong Pharmaceutical Co.,Ltd is a subsidiary of China Resources Jiangzhong Pharmaceutical Group Co., Ltd.
www.jzjt.com4,013
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 600750.SS
View MorePerformance Overview: 600750.SS
Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600750.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600750.SS
View MoreValuation Measures
Market Cap
14.38B
Enterprise Value
13.47B
Trailing P/E
19.21
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.50
Price/Book (mrq)
3.87
Enterprise Value/Revenue
3.27
Enterprise Value/EBITDA
13.89
Financial Highlights
Profitability and Income Statement
Profit Margin
18.19%
Return on Assets (ttm)
9.18%
Return on Equity (ttm)
18.40%
Revenue (ttm)
4.13B
Net Income Avi to Common (ttm)
750.31M
Diluted EPS (ttm)
1.19
Balance Sheet and Cash Flow
Total Cash (mrq)
907.98M
Total Debt/Equity (mrq)
0.04%
Levered Free Cash Flow (ttm)
876.08M